Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives.
Six oversulfated dermatan sulfate (DS) derivatives, differing in their tissue origin (porcine skin, bovine and porcine intestinal mucosa), and the oversulfation method of preparation, have been tested for their anticoagulant properties. In the first method, the SO3-trimethylamine complex is added to a DS sodium salt dissolved in formamide while it is added to a DS-benzethonium salt dissolved in dimethyl formamide in the second method. The rate of sulfation of these compounds ranged from 7.8 to 11.5 percent of sulfur on a weight basis, whereas it is 6% and 12% for natural DS and for heparin respectively. The anticoagulant potency was assessed by determining the catalytic effect of each glycosaminoglycan on the inhibition of thrombin added to (i) plasma (ii) purified heparin cofactor II(HC II) or (iii) purified antithrombin III(AT III). The catalytic effect on Factor Xa inhibition in the presence of AT III has also been investigated. The increased sulfation is found to enhance the antithrombin activity of the native dermatan sulfate whatever the method used, while the Factor Xa inhibition by AT III could be catalysed only by the most sulfated derivative obtained by the second method. The two derivatives which were less oversulfated, by the first oversulfation method, exhibit equal or even higher catalytic effects on thrombin inhibition when compared to the four other derivatives. The use of the first oversulfation method provides slightly oversulfated derivatives which exhibit strong anticoagulant properties and may constitute effective antithrombotic drugs with no bleeding tendency, a side effect perhaps related to a high rate of sulfation.
Maaroufi
R M
RM
Laboratoire d'Hématologie, C.H.U. Necker-Enfants Malades, Paris, France.
Tapon-Bretaudiere
J
J
Mardiguian
J
J
Sternberg
C
C
Dautzenberg
M D
MD
Fischer
A M
AM
D000818:Animals; D000925:Anticoagulants / Q000138:chemical synthesis; D000990:Antithrombin III / Q000032:analysis / Q000494:pharmacology; D002384:Catalysis; D002417:Cattle; D003871:Dermatan Sulfate / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000302:isolation & purification; D015844:Heparin Cofactor II / Q000494:pharmacology; D008722:Methods; D013329:Structure-Activity Relationship; D013431:Sulfates / Q000138:chemical synthesis; D013552:Swine
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D013431:Sulfates; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D000990:Antithrombin III; D006493:Heparin